AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05662878 — intervention group
Intervention type: OTHER
Intervention: Assessment of Hand Strength and Spasticity
Description: Assessment of Hand Strength and Spasticity
Study NCT06584747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: 18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
Study NCT06212349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic-educational physiotherapy and pain education program
Description: The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
Study NCT05066178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAS Treatment for Minimally Verbal Children with Autism
Description: Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
Study NCT05854160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Pulse Train Stimulation
Description: sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
Study NCT05708976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
Study NCT05708976 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
Study NCT05708976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Whole-Body Hyperthermia (Active WBH)
Description: Active whole-body hyperthermia (active WBH) will be administered by trained research assistants. Preparation for the active WBH session, the active WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 38.5 C.
Study NCT06212349 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pain education program
Description: They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
Study NCT05708976 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Whole-Body Hyperthermia (Sham WBH)
Description: Sham whole-body hyperthermia (sham WBH) will be administered by trained research assistants. Preparation for the sham WBH session, the sham WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the sham WBH session will minimally impact core body temperature.
Study NCT06309693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum (QL) Block
Description: The standard of care QL block will be performed by the regional anesthesia team according to their standard protocol with a uniform quantity and concentration of analgesic agent. Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
Study NCT06309693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Recovery After Surgical (ERAS) Protocol
Description: Subjects randomized to the ERAS arm will undergo the standard ERAS protocol of early postoperative ambulation, no bowel preparation, and the use of multimodal pain medications including acetaminophen and non-steroid anti-inflammatory drugs (NSAIDs). Patients will subsequently be asked about their pain postoperatively and opioid medication administration will be quantified.
Study NCT05198323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT3001 Drug Product
Description: Administered by intravenous infusion
Study NCT05198323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion
Study NCT05698888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP301
Description: VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
Study NCT04374253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
Study NCT04374253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
Study NCT05245929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distalization
Description: Distalizing the posterior maxillary segment
Study NCT06532175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Su-Jok
Description: Su-jok seed therapy
Study NCT06393049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperglycaemic clamp
Description: Following an overnight fast, the investigators will perform simultaneous samples from the arterial line, the venous line, and microdialysis and consider these samples as baseline values.~If the patient's blood glucose level is at 8-10 mmol/L at baseline, the investigators will not proceed with the intervention and instead evaluate if the intervention can take place the following day.~After baseline values are measured, intravenous glucose 20% (200g/1,000 ml) is infused to raise the glucose levels in both plasma and extravascular glucose compartments with approximately 3 mmol/L.
Study NCT06635928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: 30min daily of 10.000 lux bright light therapy
Study NCT04786444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological Vaccine VLA1553
Description: Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate
Study NCT04873921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sterile kinesio taping
Description: Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
Study NCT04668248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns.
Study NCT04668248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online educational training
Description: Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.
Study NCT05687045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
Study NCT05687045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Therapy
Description: Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
Study NCT05876065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC
Description: Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
Study NCT05876065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: Any physician's choice as maintenance therapy (except for XC regimen)
Study NCT05686733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SEAL Device
Description: Endovascular treatment of target aneurysm using the Saccular Endovascular Aneurysm Lattice (SEAL) device.
Study NCT05065463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Participants will receive a single subcutaneous (SC) dose of AZD8233 into the region of the abdomen.
Study NCT05028101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed autologous breast reconstruction
Description: SOC: Delayed autologous breast reconstruction
Study NCT05028101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed autologous breast reconstruction
Description: SOC: Delayed autologous breast reconstruction
Study NCT05028101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Functional Medicine (FM) Care
Description: SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.
Study NCT05030090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional consultant
Description: The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
Study NCT05030090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional consultant
Description: The control group is to be consulted by the dietitian using communication software (Line) or telephone to evaluate the nutritional requirement and guide the cancer diet principles before starting the project.
Study NCT05030090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional consultant + High-calorie, high-protein liquid nutrition supplement
Description: At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group A to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein).
Study NCT05532319 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HAIC sequential TAE combined with lenvatinib and tislelizumab
Description: Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
Study NCT05347524 — intervention group
Intervention type: OTHER
Intervention: Baseline blood draw and blood-based biomarkers analyses
Description: Baseline blood draw and blood-based biomarkers analyses
Study NCT04825210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Health - Prevention
Description: IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
Study NCT04825210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition
Description: Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
Study NCT05030090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutritional consultant + Liquid supplement + Powdered supplement 1 and 2
Description: At the beginning of the plan, the dietitian first calculates the patient's daily calorie intake and the ratio of the three macronutrients and guides the patients or their family members of the nutritional care plan group B to implement a daily diet with a concentrated high-calorie and high-protein liquid supplement (Commercial formula contains 425 kcal and 19.1 grams of protein). Meanwhile, nutrition care plan group B will be given powdered supplement 1 (containing β-glucan and gamma-aminobutyric acid) and nutritional products and powdered supplement 2 (contains water-soluble dietary fiber and probiotics).
Study NCT05513261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate
Description: In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
Study NCT05513261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate
Description: In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
Study NCT05556070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: : Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
Study NCT05556070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.
Study NCT05556070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3
Description: subjects in this arm will receive the usual standard of care at the clinic for the study period
Study NCT05556070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brighter Bites app
Description: Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families.
Study NCT05862779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
Study NCT05862779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein + Placebo
Description: The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
Study NCT05862779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 + Placebo
Description: The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
Study NCT05862779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 + Whey Protein
Description: The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
Study NCT05664126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VST infusion
Description: single intravenous (IV) infusion.
Study NCT05664126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Cells infusions are prepared using the ClinMACS
Study NCT03750500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback device
Description: 12-week exercise program performed through the device
Study NCT06543836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Study NCT03750500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on falls risk
Description: Education on falls risk factors and how to minimize them
Study NCT03750500 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education on falls risk
Description: Education on falls risk factors and how to minimize them
Study NCT03750500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Medication will be reviewed to reduce sedative drugs and minimize interactions
Study NCT03750500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medication review
Description: Medication will be reviewed to reduce sedative drugs and minimize interactions
Study NCT03750500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual and auditory screening
Description: Patients will go through visual and auditory screening as part of their regular care
Study NCT03750500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Visual and auditory screening
Description: Patients will go through visual and auditory screening as part of their regular care
Study NCT06543836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib or Regorafenib
Description: The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.
Study NCT06543836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Study NCT06277791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab：20mg/kg, ivdrip, D1，Q3W
Study NCT04754932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
Study NCT04831853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swabbing procedure (self swabbing first)
Description: Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
Study NCT04831853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swabbing procedure (conventionnal swabbing first)
Description: patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
Study NCT05209867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: * Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc \~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~* The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration
Study NCT05750212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tone
Description: Tone is a binary measurement of the pelvic floor muscle on physical examination